Table 3.
Outcomes of patients not undergoing surgery for primary malignant melanoma of esophagus
| No | Age | Sex | Tumor morphology | Metastases | BRAF | PD-L1 (TPS) | 1st treatment | Time to progression | 2nd treatment | Time to progression | 3rd treatment | Time to progression | Overall survival (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 64 | M | Diffusely infiltrative | LN, adrenal gland | N/A | 0% | Nivolumab | 24 months | DPT | 2 months | Trastuzumab + Deruxtecan (Clinical trial) | Alive by 2021.06.30 | 34 | Alive |
| 2 | 82 | M | Mass-forming | None | N/A | N/A | Pembrolizumab | 2 months | DPT | 8 months | Supportive care | 18 | Dead | |
| 3 | 63 | M | Mass-forming | Lung, liver, LN, adrenal gland, thyroid | N/A | N/A | DBPT | 2 months | IFN α | 2 months | Supportive care | 10 | Dead | |
| 4 | 83 | M | Mass-forming | None | N/A | N/A | Supportive care | 6 | Dead | |||||
| 5 | 60 | M | Mass-forming | Bone, LN | Not detected | N/A | RT | 1 week | DPT | 2 months | Ipilimumab | 1 month | 5 | Dead |
PD-L1 programmed death-ligand 1, TPS tumor proportion score, M male, LN lymph node, DPT Dacarbazine + Cisplatin ± Tamoxifen, DBPT Dacarbazine + Carmustine + Cisplatin ± Tamoxifen, RT radiotherapy, IFN-α interferon alpha, N/A not available